INCIDENCE OF ANOGENITAL WARTS IN LIUZHOU, SOUTH CHINA: A COMPARISON OF DATA FROM A PROSPECTIVE STUDY AND FROM THE NATIONAL SURVEILLANCE SYSTEM

Feixue Wei1, Wei Sheng1, Xin Wu2, Kai Yin2, Jian Lan2, Yue Huang1, Xinjing Ma1, Ya Zheng1, Sijie Zhuang1, Shoujie Huang1, Yingying Su1, Mingqiang Li2, Ting Wu1, Jun Zhang1 and Ningshao Xia1

To determine the incidence of anogenital warts (AGWs) in the Chinese general population, we compared the data from a prospective study and from the National Notifiable Disease Report System (NNDRS). A cohort study including 2378 women and 2309 men aged 18–55 years old enrolled from Liuzhou, China, was conducted with three scheduled visits at 6-month intervals from May 2014 to March 2016. And, a questionnaire survey was performed to collect the diagnosis history of AGWs at the enrollment visit. The data on reported AGW cases of Liuzhou in the NNDRS from 2006 to 2015 were also analyzed. Overall, the incidence rates of AGWs in the prospective study, in the self-reported diagnosis during past 12 months and in the NNDRS were 1.26 per 1000 person-years (95% confidence interval [CI]: 1.17–1.35), 2.35 (95% CI: 1.17–4.20) and 0.183 (95% CI: 0.178–0.187), respectively. Human papillomavirus 6 or 11 were found in all the AGW biopsy samples (10/10). The onset time of AGWs in women was earlier, and the cumulative risk increased more quickly at a young age along with each subsequent younger birth cohort (P<0.0001), whereas slight differences were observed in the different male birth cohorts (P=0.0785). The sexual behavior of individuals and their sexual partners had a strong relationship with self-reported AGWs. Our study indicates that the incidence of AGWs in China is as high as that in developed countries, and the data based on the national surveillance system seriously underestimate the real disease burden of AGWs.

Emerging Microbes & Infections (2017) 6, e113; doi:10.1038/emi.2017.100; published online 20 December 2017

Keywords: anogenital warts; human papillomavirus; incidence; prevalence; risk factors

INTRODUCTION

Anogenital warts (AGWs), also called genital warts or condyloma acuminata, is a common sexually transmitted disease (STD) in both men and women.1 Patients with AGWs suffer both physical (burning, bleeding, itching and pain) and psychosocial stress (anxiety, decreased self-esteem, and negative emotional and sexual impact).2–4 The recurrence of AGWs is common, with the rate ranging from 6% to 77%, which has further increased the economic burden of medical health care and the psychosocial impact on patients.5,6 Previously, it was thought that AGWs were benign and not life threatening; however, recently, a Danish study indicated that individuals with AGWs had a long-term increased risk of anogenital cancers and head and neck cancers, which may due to coinfection with oncogenic human papillomavirus (HPV), having high-risk behavioral factors (e.g., a higher number of partners, or a higher consumption of alcohol or smoking) or the poor immunity of the patients.7

The incidence rates of AGWs among the general population worldwide are 1.6–2.8 per 1000 person-years,8 and the higher rates, over 10 per 1000 person-years, were reported in 15–26-year-old people,9,10 sex workers,11 men who have sex with men12,13 and HIV-infected individuals.13 In China, data regarding the incidence rate of AGWs mainly come from the National Notifiable Disease Report System (NNDRS); however, as AGWs is not a mandatory reported disease, many AGW cases are missed. The reported incidence rates from the NNDRS, which were 0.24–0.30 per 1000 person-years from 2008 to 2016, might severely underestimate the real disease burden of AGWs in China.14 and data from the general population based on cohort studies are scarce.

HPV types 6 and 11 cause more than 90% of the cases of AGWs.15 The administration of HPV vaccines containing HPV 6 and 11 antigens is the highly effective approach for preventing AGWs. After the introduction of the national quadrivalent HPV (types 6, 11, 16 and 18, Gardasil) vaccination program, a significant decline in diagnosed AGWs at the population level has been reported in Australia,16,17 Denmark18–20 and the United States.21 Further, a recent ecological study in England, where a bivalent HPV vaccine (types 16 and 18, Cervarix) program was introduced in 2008, has shown a reduction in the rates of AGW diagnoses in males and females (25.4% and 30.6%, respectively) from 2009 to 2014.22 Gardasil and Cervarix were licensed in China in May 2017 and July 2016, respectively. Uncovering the real

1State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceuticals, School of Public Health, Xiamen University, Xiamen 361102, Fujian, China and 2Liuzhou Center for Disease Control and Prevention, Liuzhou 545027, Guangxi, China

Correspondence: Ting Wu or MQ Li

E-mail: wuting@xmu.edu.cn or lzscdclmq@126.com

Received 21 July 2017; revised 18 October 2017; accepted 31 October 2017
Table 1 Baseline characteristics of men and women in the analyzed cohort and the full cohort in the prospective study

| Variables                        | Analyzed cohort<sup>a</sup> | Full cohort          |
|----------------------------------|-----------------------------|----------------------|
|                                  | Men (n = 1821)              | Women (n = 2045)     | Men (n = 2309)          | Women (n = 2378)          |
| Birth cohort (year)<sup>b</sup>  |                              |                      |                        |                            |
| 1989–1996                        | 256 (14.1)                  | 295 (14.4)           | 396 (17.2)             | 421 (17.7)                 |
| 1979–1988                        | 458 (25.1)                  | 537 (26.3)           | 619 (26.8)             | 638 (26.8)                 |
| 1969–1978                        | 532 (29.2)                  | 567 (27.7)           | 645 (27.9)             | 618 (26.0)                 |
| 1959–1968                        | 575 (31.6)                  | 646 (31.6)           | 649 (28.1)             | 701 (29.5)                 |
| Region                           |                              |                      |                        |                            |
| Rural                            | 747 (41.0)                  | 1166 (57.0)          | 894 (38.7)             | 1391 (58.5)                |
| Urban                            | 1074 (59.0)                 | 879 (43.0)           | 1415 (61.3)            | 987 (41.5)                 |
| Education (years)                |                              |                      |                        |                            |
| <12                              | 1454 (79.8)                 | 1684 (82.3)          | 1837 (79.6)            | 1956 (82.3)                |
| ≥12                              | 367 (20.2)                  | 361 (17.7)           | 472 (20.4)             | 422 (17.7)                 |
| Income (CNY)                     |                              |                      |                        |                            |
| <50 000                          | 1364 (74.9)                 | 1620 (79.2)          | 1733 (75.1)            | 1890 (79.5)                |
| ≥50 000                          | 457 (25.1)                  | 425 (20.8)           | 576 (24.9)             | 488 (20.5)                 |
| Marital status<sup>c</sup>       |                              |                      |                        |                            |
| Married/cohabitating             | 1435 (78.8)                 | 1756 (85.9)          | 1732 (75.0)            | 1967 (82.7)                |
| Single/divorced/separated/widowed| 386 (21.2)                  | 289 (14.1)           | 577 (25.0)             | 411 (17.3)                 |
| Ever having a sauna              |                              |                      |                        |                            |
| No                               | 1219 (66.9)                 | 1510 (73.8)          | 1566 (67.8)            | 1747 (73.5)                |
| Yes                              | 602 (33.1)                  | 535 (26.2)           | 743 (32.2)             | 631 (26.5)                 |
| Ever used a towel supplied by the sauna |                      |                        |                        |                            |
| No                               | 1309 (71.9)                 | 1653 (80.8)          | 1676 (72.6)            | 1906 (80.2)                |
| Yes                              | 512 (28.1)                  | 392 (19.2)           | 633 (27.4)             | 472 (19.8)                 |
| Ever stayed in a hotel           |                              |                      |                        |                            |
| No                               | 323 (17.7)                  | 707 (34.6)           | 391 (16.9)             | 807 (33.9)                 |
| Yes                              | 1498 (82.3)                 | 1338 (65.4)          | 1918 (83.1)            | 1571 (66.1)                |
| Ever used a towel supplied by the hotel |                      |                        |                        |                            |
| No                               | 702 (38.6)                  | 1299 (63.5)          | 871 (37.7)             | 1472 (61.9)                |
| Yes                              | 1119 (61.4)                 | 746 (36.5)           | 1438 (62.3)            | 906 (38.1)                 |
| Age at time of first sexual intercourse |                      |                        |                        |                            |
| <18 years                        | 130 (7.1)                   | 108 (5.3)            | 190 (8.2)              | 145 (6.1)                  |
| 18–25 years                      | 1391 (76.4)                 | 1720 (84.1)          | 1769 (76.6)            | 1999 (84.1)                |
| ≥26 years                        | 300 (16.5)                  | 217 (10.6)           | 350 (15.2)             | 234 (9.8)                  |
Table 1 (Continued)

| Variables                                    | Men (n = 1821) | Women (n = 2045) | Men (n = 2309) | Women (n = 2378) |
|----------------------------------------------|----------------|------------------|----------------|------------------|
| **Lifetime number of sexual partners**       |                |                  |                |                  |
| 1                                            | 847 (46.5)     | 1372 (67.1)      | 1040 (45.0)    | 1554 (65.4)      |
| 2–3                                          | 563 (30.9)     | 592 (28.9)       | 731 (31.7)     | 726 (30.5)       |
| ≥4                                           | 411 (22.6)     | 81 (4.0)         | 538 (23.3)     | 98 (4.1)         |
| **Number of sexual partners in past year**   |                |                  |                |                  |
| 0–1                                          | 1553 (85.3)    | 1963 (96.0)      | 1962 (85.0)    | 2270 (95.5)      |
| ≥2                                           | 268 (14.7)     | 82 (4.0)         | 347 (15.0)     | 108 (4.5)        |
| **Sexual partners having sex with others**   |                |                  |                |                  |
| No                                           | 681 (37.4)     | 813 (39.8)       | 874 (37.9)     | 971 (40.8)       |
| Yes                                          | 76 (4.2)       | 92 (4.5)         | 104 (4.5)      | 108 (4.5)        |
| Unknown                                      | 1064 (58.4)    | 1140 (55.8)      | 1331 (57.6)    | 1299 (54.6)      |
| **Previous STD diagnosis**                   |                |                  |                |                  |
| No                                           | 1683 (92.4)    | 1693 (82.8)      | 2137 (92.6)    | 1984 (83.4)      |
| Yes                                          | 138 (7.6)      | 352 (17.2)       | 172 (7.4)      | 394 (16.6)       |
| **Frequency of condom use**                  |                |                  |                |                  |
| Never                                        | 858 (47.1)     | 1142 (55.8)      | 1079 (46.7)    | 1275 (53.6)      |
| Sometimes                                    | 566 (31.1)     | 579 (28.3)       | 712 (30.8)     | 698 (29.4)       |
| Always                                       | 397 (21.8)     | 324 (15.8)       | 518 (22.4)     | 405 (17.0)       |

Abbreviations: Chinese Yuan, CNY; sexually transmitted disease, STD.

- Men and women who were free of anogenital warts at baseline and who had at least one follow-up visit.
- Significant difference between the analyzed cohort and full cohort at \( P < 0.05 \) using \( \chi^2 \) test in both men and women.
incidence rate of AGWs in China before HPV vaccination is essential to understand the effectiveness of the licensed HPV vaccines in China.

The purpose of this study was to investigate the prevalence and incidence of AGWs in the Chinese general population through the comparison of data from a prospective study and from the national surveillance system. In addition, we estimated the risk factors associated with self-reported history of clinically diagnosed AGWs.

MATERIALS AND METHODS

Data sources

The prospective study. From May to July 2014, 2309 males and 2378 females aged 18–55 years were enrolled from the general population via media advertising, flyers, posters and educational presentations in Liuzhou City, Guangxi, China. The details of the selection criteria of the population and the methods of testing have been described elsewhere.23 Volunteers were requested to attend three scheduled visits at 6-month intervals for 1 year to investigate the natural history of AGWs. At each visit, the volunteers underwent a clinical examination by trained clinicians to identify whether there were AGWs lesions in cervical, vaginal, vulvar, anal and perianal sites of women or in external genital, anal and perianal sites of men. For cases that were diagnosed with AGWs based on their clinical appearance, biopsy samples were obtained to be tested for HPV DNA and genotyped by PCR assay. The kits tested for 13 oncogenic HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) and 3 non-oncogenic HPV types (HPV 6, 11 and 66). The study was approved by the Ethics Committee of Liuzhou Center for Disease Control and Prevention (CDC). Informed consent was given by all study volunteers.

At the enrollment visit, a questionnaire survey was conducted by a trained interviewer to collect information about ever having had a diagnosis of AGWs, the age at first diagnosis of AGWs, AGWs during the previous 12 months, ever having had a recurrence of AGWs and ever having sexual partners with previous episodes of STDs, including trichomoni-asis, genital chlamydia infection, genital herpes, syphilis, gonorrhea and chancroid. Furthermore, we collected information regarding sociodemographic variables, hygienic habits and sexual behaviors with the questionnaire.

The national surveillance system. The NNDRS is a real-time, web-based, disease surveillance system that monitors 36 notifiable and non-notifiable diseases in China. It was established in 2003 after the able diseases in China. It was established in 2003 after the

Table 2 Characteristics of prevalent and incident patients in the prospective study

| ID | Sex | Age (years) | Onset time | Lesion sites         | HPV types |
|----|-----|-------------|------------|----------------------|-----------|
| 1  | Female | 50        | Visit 1    | Cervix              | 6         |
| 2  | Female | 34        | Visit 1    | Vulva               | 6, 11, 16 and 18 |
| 3  | Female | 32        | Visit 1    | Vulva               | 6         |
| 4  | Female | 27        | Visit 1    | Vulva               | 6 and 16  |
| 5  | Female | 28        | Visit 1    | Vulva and anal      | 6         |
| 6  | Male   | 22        | Visit 1    | Anal                | 11        |
| 7a | Male   | 31        | Visit 1    | Penis               | —         |
| 8  | Female | 52        | Visit 2    | Vulva               | 6         |
| 9  | Female | 38        | Visit 3    | Vulva               | 6, 11, 16 and 18 |
| 10 | Female | 22        | Visit 3    | Vulva               | 6, 11, 16 and 18 |
| 11 | Female | 21        | Visit 3    | Vagina              | 6         |
| 12a| Female | 20        | Visit 3    | Vulva and perianal  | —         |

Abbreviation: human papillomavirus, HPV.

aBiopsy samples of anogenital warts were not collected because of loss to follow-up.

Incidence of anogenital warts in China
F Wei et al
Emerging Microbes & Infections

The national surveillance system. The incidence rates of AGWs by sex in NNDRS were calculated by using the total number of cases during the annual period divided by the local annual population at the time at risk. Temporal trends in the incidence from 2006 to 2015 were examined by fitting jointpoint models. The annual percentage change (APC) was used to express the trends, and the Z-test was used to assess whether the APC was significantly different from zero. To clarify the age distribution of the incidence by sex, we also calculated the average age-specific incidence rate of men and women.

To compare data from different sources, the incidence rates were reported per 1000 person-years in both the prospective study and the outbreak of Severe Acute Respiratory Syndrome. It consists of a five-level network from the township to the national level and a three-level platform from prefecture to the national level. Infectious diseases are reported to the local disease reporting system within 2 h (class A infectious diseases) or 24 h (class B or C infectious diseases) post diagnosis in hospitals or other health facilities. To ensure the quality of the reports, the data are reviewed by the local CDC, then a correction or supplementary report is made if necessary.

AGWs is one of the non-notifiable diseases, and is monitored as one of the STDs according to the National Guidelines of Surveillance for Sexually Transmitted Diseases by the NNDRS in China. According to the guidelines, only the first episode patients were reported, whereas the return visit patients and recurrence patients were not reported. The cases were diagnosed according to the Diagnostic Criteria and Principles of Management of Condyloma Acuminatum (WS235–2003). The data of AGWs in Liuzhou City from 1 January 2006 to 31 December 2015 from the NNDRS were analyzed. Local population data by age, group and sex between 2006 and 2015 were obtained from the Liuzhou Statistics Department.

Statistical analysis

The prospective study. The participants who were free of AGWs at baseline and who had at least one follow-up visit were included in the analysis for the prospective study. Pearson's \( \chi^2 \) tests were used to compare the sociodemographic, hygienic and sexual behavioral characteristics of men and women in the analyzed cohort and the full cohort. The incidence of AGWs was estimated by dividing the number of cases by the number of person-years of participants. Person-years were regarded as the number of years from the date of enrollment until the date that AGWs were observed or until the date of the last visit for those who did not develop AGWs. The calculation of the 95% confidence intervals (CIs) of the incidence was based on the number of events modeled as a Poisson variable for the total person-years. In addition, we calculated the prevalence of AGWs in the full cohort at baseline.

For data from the questionnaire survey, we assessed the incidence of AGWs during the previous 12 months by sex. The proportion of volunteers who had self-reported AGWs during a lifetime was also estimated. Based on the age at first diagnosis of AGWs, the Kaplan–Meier method was used to calculate the cumulative age-specific incidence, with strata by birth cohort (i.e., birth in 1959–1968, 1969–1978, 1979–1988 and 1989–1996). Comparisons among different birth cohorts were performed by the log-rank test. Odds ratios (ORs) and the corresponding 95% CIs of the risk factors associated with the self-reported AGWs were calculated by bivariate and multivariate logistic regression. Variables with \( P < 0.20 \) in the bivariate analysis were put into the multivariate model and then selected stepwise, with a 0.05 significance level for entry and 0.05 for removal.

The national surveillance system. The incidence rates of AGWs by sex in NNDRS were calculated by using the total number of cases during the annual period divided by the local annual population at the time at risk. Temporal trends in the incidence from 2006 to 2015 were examined by fitting jointpoint models. The annual percentage change (APC) was used to express the trends, and the Z-test was used to assess whether the APC was significantly different from zero. To clarify the age distribution of the incidence by sex, we also calculated the average age-specific incidence rate of men and women.

To compare data from different sources, the incidence rates were reported per 1000 person-years in both the prospective study and the
Table 3 Prevalence and incidence of anogenital warts by sex based on data from the prospective study and from the national surveillance system

| Variables                                                                 | Males                   | Females                  | Total                    |
|---------------------------------------------------------------------------|-------------------------|--------------------------|--------------------------|
| **Prevalence (%), 95% CI**                                                |                         |                          |                          |
| Self-reported a lifetime history of AGWs in the prospective study         | 1.73 (1.24, 2.35)       | 1.14 (0.75, 1.65)        | 1.43 (1.11, 1.81)        |
| Cases diagnosed at baseline in the prospective study                     | 0.09 (0.01, 0.31)       | 0.21 (0.07, 0.49)        | 0.15 (0.06, 0.31)        |
| **Incidence (/1000 person-years, 95% CI)**                               |                         |                          |                          |
| Follow-up data in the prospective study                                  | 0                      | 2.37 (0.30, 4.45)        | 1.26 (0.16, 2.37)        |
| Self-reported data during the past 12 months in the prospective study    | 1.73 (0.36, 3.42)       | 2.94 (0.77, 5.12)        | 2.35 (1.17, 4.20)        |
| Data in the national surveillance system                                 | 0.165 (0.159, 0.171)    | 0.202 (0.196, 0.209)     | 0.183 (0.178, 0.187)     |

Abbreviations: anogenital warts, AGWs; confidence interval, CI.
*aData show the average incidence of AGWs from 2006 to 2015.

Figure 1  Kaplan–Meier estimates of the cumulative incidence of self-reported clinically diagnosed anogenital warts by birth cohort in the prospective study in men (A) and women (B). Based on age at first diagnosis of anogenital warts, the cumulative incidence of anogenital warts (up to that time) was calculated. The log-rank test was used to analyze the differences among different birth cohorts.
$$n/(\%$$ OR (95% CI) AOR (95% CI)$^a$

| Birth cohort (year) | $n/(\%)$ | OR (95% CI) | AOR (95% CI)$^a$ |
|---------------------|----------|-------------|------------------|
| 1989–1996           | 6 (0.7)  | 1.0         | —                |
| 1979–1988           | 23 (1.8) | 2.5 (1.0, 6.2) | —                |
| 1969–1978           | 24 (1.9) | 2.6 (1.1, 6.4) | —                |
| 1959–1968           | 14 (1.0) | 1.4 (0.5, 3.7) | —                |

| Sex                 | $n/(\%)$ | OR (95% CI) | AOR (95% CI)$^a$ |
|---------------------|----------|-------------|------------------|
| Female              | 27 (1.1) | 1.0         | —                |
| Male                | 40 (1.7) | 1.5 (0.9, 2.5) | —                |

| Ever having a sauna | $n/(\%)$ | OR (95% CI) | AOR (95% CI)$^a$ |
|---------------------|----------|-------------|------------------|
| No                  | 28 (0.8) | 1.0         | 1.0              |
| Yes                 | 39 (2.8) | 3.4 (2.1, 5.6) | 2.0 (1.2, 3.4)   |

| Lifetime number of sexual partners | $n/(\%)$ | OR (95% CI) | AOR (95% CI)$^a$ |
|-----------------------------------|----------|-------------|------------------|
| 1                                 | 17 (0.7) | 1.0         | 1.0              |
| 2–3                               | 21 (1.4) | 2.2 (1.2, 4.2) | 1.6 (0.8, 3.2)  |
| ≥4                                | 29 (4.6) | 7.2 (4.0, 13.3) | 4.1 (2.1, 7.9)  |

| Sexual partners having sex with others | $n/(\%)$ | OR (95% CI) | AOR (95% CI)$^a$ |
|---------------------------------------|----------|-------------|------------------|
| No                                    | 24 (1.3) | 1.0         | 1.0              |
| Yes                                   | 13 (6.1) | 5.0 (2.5, 9.9) | 2.4 (1.2, 5.1)  |
| Unknown                               | 30 (1.1) | 0.9 (0.5, 1.5) | 0.8 (0.4, 1.3)  |

| Sexual partners having a previous STD diagnosis | $n/(\%)$ | OR (95% CI) | AOR (95% CI)$^a$ |
|-------------------------------------------------|----------|-------------|------------------|
| No                                              | 47 (1.1) | 1.0         | 1.0              |
| Yes                                             | 20 (7.5) | 7.6 (4.4, 13.0) | 4.3 (2.4, 7.5)  |

---

**RESULTS**

**The prospective study**

A total of 3866 individuals, including 1821 men and 2045 women who were free of AGWs at baseline and who had at least one follow-up visit, were included in the analyzed cohort. Men and women in the analyzed cohort and the full cohort were comparable for most of the demographic and behavioral characteristics, excluding birth cohort and marital status (Table 1).

The median follow-up time was 12.5 months (interquartile range 12.1–13.1) for males and 12.6 months (interquartile range 12.5–13.0) for females. During the follow-up period, one female at Visit 2 and four females at Visit 3 developed AGWs (Table 2), and the incidence rate was 2.37/1000 person-years (95% CI: 0.30–4.45) (Table 3). None of the males was diagnosed with AGWs during follow-ups in the study period. At baseline, two (0.09%) males and five (0.21%) females were diagnosed with AGWs. Regardless of prevalent or incident cases, no recurrences were observed after treatment.

Because of loss to follow-up, we collected biopsy samples from 83% (10/12) of the prevalent and new incident AGW cases (Table 2). All samples were positive for HPV 6 or 11, and four samples were coinfected with HPV 16 or 18.

For all volunteers in the full cohort, 1.73% (40/2309) of the males and 1.14% (27/2378) of the females reported having at least one episode of clinically diagnosed AGWs during their lifetime (Table 3). Females generally acquired AGWs somewhat earlier than males (median age = 26 years for females and 30 years for males), although no significant difference by sex was found ($P = 0.1108$). Among the patients, 12.5% of the males and 18.5% of the females reported that they had at least one recurrence of AGWs. The incidence of self-reported, diagnosed AGWs during the past 12 months was 1.73 (95% CI: 0.36–3.42) per 1000 person-years for males and 2.94 (95% CI: 0.77–5.12) per 1000 for females, and no sex differences were found.

Figure 1 shows the cumulative incidence of self-reported diagnosed AGWs among men and women by birth cohort based on age at first diagnosis. In men, the cumulative incidence of AGWs was comparable among the different birth cohorts ($P = 0.0785$); however, in women, the age at first diagnosis was earlier, and the cumulative incidence risk increased with each subsequent younger birth cohort ($P < 0.0001$).

We estimated the risk factors associated with self-reported diagnosis of AGWs (Table 4). In the multivariate analysis, individuals whose sexual partners having a STD diagnosis (OR = 4.3, 95% CI: 2.4–7.5) and who had more than three lifetime sexual partners (compared with 1, OR = 4.1, 95% CI: 2.1–7.9) had higher risk to reported AGWs. In addition, sexual partners having sex with others (OR = 2.4, 95% CI: 1.2–5.1) and having a sauna (OR = 2.0, 95% CI: 1.2–3.4) increased the probability of self-reported AGWs.

The **national surveillance system study**

A total of 3245 males and 4430 females in Liuzhou City were diagnosed with AGWs in the NNDRS from 2006 to 2015. The average incidence was 0.165 per 1000 person-years in men and 0.202 per 1000 in women (Table 3). The annual AGWs incidence decreased from 0.26 to 0.13 per 1000 person-years among males from 2006 to 2015 ($APC = –6.20, P < 0.01$). Among females, it decreased from 0.39 to 0.15 per 1000 during 2006 to 2010 ($APC = –19.64, P < 0.01$), then the stable trend was seen from 2010 to 2015 ($APC = –2.41, P = 0.70$) (Figure 2).

The average age-specific incidence rate of AGWs was highest for 20–24-year-old females (0.64/1000 person-years), while the rate peaked at a slightly older age of 25–29 years in males (0.46/1000 person-years) (Figure 3). Most of the AGW cases in the NNDRS were...
and 18 was also found in subjects with AGWs. AGW cases coinfected with high-risk HPV types were at a higher risk of suffering anogenital cancers and head and neck cancers, so more attention should be paid to consecutively monitor these infections after treatment.

Based on the self-reported AGWs during a lifetime, men had a higher prevalence than women; however, the reverse was observed in the prospective study and for the self-reported AGW cases during the past 12 months. In fact, it is a disputed issue whether there are sex-based discrepancies in the incidence of AGWs. The epidemiological studies, however, have consistently confirmed that women have an earlier peak incidence age than men. In our study, 20–25-year-old females and 25–30-year-old males had the highest incidence rate. This age-specific variation may be due to sexual mixing patterns, where younger women tended to have sex with older men. Another potential cause may be that females had a shorter incubation period of HPV 6 or 11 than men. After the incident HPV 6 or 11 infection, the median time of developing AGWs was 2.9 months in women, whereas it was 11 months in males. The longer period in men may be the reason why no male cases were observed during the 1-year period of our prospective study.

Based on the analysis of different birth cohorts by sex, we found that the onset time of AGWs in women was earlier, and the cumulative risk increased more quickly at a young age along with each subsequent younger birth cohort, whereas only slight differences occurred in the different male birth cohorts. Future studies with larger sample size should take into consideration to interpret the sex differences; however, the phenomenon in the present study revealed that the main target population of the HPV vaccine should be carefully selected to make sure it is given before sexual debut, especially for women. For men, the vaccination of older birth cohorts might be warranted because of the stable cumulative risk of AGWs with age.

Similar to most studies, we found that sexual behavior was associated with self-reported clinically diagnosed AGWs. As the CDC recommends, altering sexual behavior by limiting the number of sexual partners and correctly using condoms are methods to avoid HPV infection. In addition, we found that ever having used a sauna was also associated with contracting AGWs, which reflected that developing good health habits could reduce the risk of incident AGWs.

Limitations existed in our study. First, as volunteers were enrolled in this study, the results presented here might have bias when generalized to the whole population in China. Second, although one-to-one questionnaire interviews in an independent room were conducted by a same-sex trained investigator, social desirability bias might occur when we collected the information about sexual behavior and other factors. Furthermore, the follow-up period is only 1 year in this study, which is similar to the median time from incident HPV 6 or 11 infection to the lesion development among males, coupled with men who contracted AGWs are more easily to recognize the lesions and refuse to continue the visits. Therefore, our perspective study may underestimate the incidence of AGWs in men.

In conclusion, the incidence of AGWs in China is as high as that in developed countries, and the data based on the national surveillance system seriously underestimate the real disease burden of AGWs in China.

ACKNOWLEDGEMENTS

This work was supported by National Natural Science Foundation of China (81673240 to TW and 81601805 to YS), National Science and Technology Major Project (2015ZX09101034 to NX) and Fujian Provincial Major Scientific and Technological Project (2014Y2004 to NX).
Incidence of anogenital warts in China

F Wei et al

1 Wiley DJ, Douglas J, Beutner K et al. External genital warts: diagnosis, treatment, and prevention. *Clin Infect Dis* 2002; 35(Suppl 2): S210–S224.

2 Pirotta M, Ung L, Stein A et al. The psychosocial burden of human papillomavirus related disease and screening interventions. *Sex Transm Infect* 2009; 85: S08–S13.

3 Wang SM, Shi JF, Kang DJ et al. Impact of human papillomavirus-related lesions on quality of life: a multicenter hospital-based study of women in Mainland China. *Int J Gynecol Cancer* 2011; 21: 182–188.

4 Maw RD, Retiana M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. *Int J STD AIDS* 1998; 9: 571–578.

5 Yanofsky VR, Patel RV, Goldenberg G. Genital warts: a comprehensive review. *J Clin Aesthet Dermatol* 2012; 5: 25–36.

6 O’Mahony C. Genital warts: current and future management options. *Am J Clin Dermatol* 2008; 9: 239–243.

7 Blomberg M, Fries S, Munk C et al. Genital warts and risk of cancer: a Danish study of nearly 50 000 patients with genital warts. *J Infect Dis* 2012; 205: 1544–1553.

8 Patel H, Wagner M, Singhal P et al. Systematic review of the incidence and prevalence of genital warts. *BMC Infect Dis* 2013; 13: 39.

9 Giuliano AR, Palefsky JM, Goldstone S et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. *N Engl J Med* 2011; 364: 401–411.

10 Garland SM, Steben M, Sings HL et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. *J Infect Dis* 2009; 199: 805–814.

11 Su S, Chow EP, Muessig KE et al. Sustained high prevalence of viral hepatitis and sexually transmissible infections among female sex workers in China: a systematic review and meta-analysis. *BMC Infect Dis* 2016; 16: 2.

12 Jin F, Prestage GP, Kippax SC et al. Risk factors for genital and anal warts in a prospective cohort of HIV-negative homosexual men: the HIM study. *Sex Transm Dis* 2007; 34: 488–493.

13 Banura C, Mirembe FM, Orem J et al. Prevalence, incidence and risk factors for anogenital warts in sub Saharan Africa: a systematic review and meta analysis. *Infect Agent Cancer* 2013; 8: 27.

14 Yue X, Gong X, Li J et al. Epidemiological features of condyloma acuminatum in national sexually transmitted disease surveillance sites in China from 2008 to 2016. *Chin J Dermatol* 2017; 50: 321–325. Chinese.

15 Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. *Vaccine* 2006; 24 (Suppl 3): 35–41.

16 Harrison C, Brit H, Garland S et al. Decreased management of genital warts in young women in Australian general practice post introduction of national HPV vaccination program: results from a nationally representative cross-sectional general practice study. *PLoS One* 2014; 9: e105967.

17 Donovan B, Franklin N, Guy R et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. *Lancet Infect Dis* 2011; 11: 39–44.

18 Baandrup L, Blomberg M, Dehlendorff C et al. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. *Sex Transm Dis* 2013; 40: 130–135.

19 Blomberg M, Dehlendorff C, Munk C et al. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. *Clin Infect Dis* 2013; 57: 929–934.

20 Bollmer S, Baldur-Feksov B, Blomberg M et al. Significant reduction in the incidence of genital warts in young men 5 years after the danish human papillomavirus vaccination program for girls and women. *Sex Transm Dis* 2016; 43: 238–242.

21 Perkins RB, Legler A, Hanchate A. Trends in male and female genital warts among adolescents in a safety-net health care system 2004–2013: correlation with introduction of female and male human papillomavirus vaccination. *Sex Transm Dis* 2015; 42: 665–668.

22 Canvin M, Sinka K, Hughes G et al. Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis. *Sex Transm Infect* 2017; 93: 125–128.

23 Wei F, Yin K, Wu X et al. Human papillomavirus prevalence and associated factors in women and men in south China: a population-based study. *Emerg Microbes Infect* 2016; 5: e119.

24 Brown DR, Schroder JM, Bryan JT et al. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. *J Clin Microbiol* 1999; 37: 3316–3322.

25 Leval A, Herweijer E, Arnhim-Dahstrom L et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. *J Infect Dis* 2012; 206: 860–866.

26 Steben M, Ouhoummane N, Rodier C et al. Temporal trends in genital warts among individuals covered by the public prescription drug insurance plan in the province of Quebec, Canada, from 1998 to 2007. *J Low Genit Tract Dis* 2013; 17: 147–153.

27 Pirotta M, Stein AN, Conway EL et al. Genital warts incidence and healthcare resource utilisation in Australia. *Sex Transm Infect* 2010; 86: 181–186.

28 Winer RL, Kiviat NB, Hughes JP et al. Development and duration of human papillomavirus lesions, after initial infection. *J Infect Dis* 2005; 191: 731–738.

29 Arima Y, Winer RL, Feng Q et al. Development of genital warts after incident detection of human papillomavirus infection in young men. *J Infect Dis* 2010; 202: 1181–1184.

30 Petras M, Adamkova V. Rates and predictors of genital warts burden in the Czech population. *Int J Infect Dis* 2015; 35: 29–33.

31 Kjaer SK, Tran TN, Sparen P et al. Temporal trends in genital warts among adolescents in a safety-net health care system 2004–2013: correlation with introduction of female and male human papillomavirus vaccination. *Sex Transm Dis* 2015; 43: 640–644.

32 Munk C, Nielsen A, Liaw KL et al. Development and duration of human papillomavirus-related lesions from otherwise healthy and immunosuppressed patients. *J Clin Microbiol* 1999; 37: 3316–3322.